HL 036

Drug Profile

HL 036

Alternative Names: Anti-TNF-alpha protein - HanAll Biopharma; HL036; TNF-alpha blocker - HanAll Biopharma

Latest Information Update: 15 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator HanAll Biopharma
  • Developer HanAll Biopharma; Unknown
  • Class Biobetters; Eye disorder therapies; Recombinant proteins
  • Mechanism of Action Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Dry eyes
  • Research Diabetic retinopathy; Wet age-related macular degeneration

Most Recent Events

  • 12 Sep 2017 HanAll BioPharma plans to initiate a phase II clinical trial for Dry eyes in the US by the end of November 2017
  • 12 Sep 2017 HL-036 licensed to Harbour BioMed in Greater China, including Hong Kong, Macau and Taiwan
  • 12 Sep 2017 Early research in Diabetic retinopathy in Japan, South Korea (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top